-
Cooperation between pharmaceutical companies and AI companies has become a general trend in the industry, and innovations may accelerate
Time of Update: 2021-12-29
In addition to Hengrui Medicine, in September this year, Jingxin Pharmaceutical and AI drug research and development company Jingtai Technology also reached a project cooperation to jointly promote the research and development of small molecule antidepressant drugs .
-
Talents from multinational pharmaceutical companies are accelerating their transfer to China, and local pharmaceutical companies have both opportunities and challenges
Time of Update: 2021-12-29
Recently, AstraZeneca officially announced to employees that Yin Min, head of AstraZeneca’s China Oncology Division, and Wang Dong, head of retail division, have decided to leave AstraZeneca to seek e
-
New indication of Haisco's "Cycloprofen" approved
Time of Update: 2021-12-29
According to the Insight database, Haisco has currently initiated 6 phase 3 clinical trials for cycloporol, 5 of which have been completed, which most likely corresponds to the 5 indications declared by it .
-
Industry recommendations: Layout of pharmaceutical manufacturing upgrades in 2022, focusing on the upstream of biomedicine
Time of Update: 2021-12-29
The industry predicts that in the future, domestic biopharmaceutical equipment companies such as Dongflon and Chutian Technology are expected to accelerate the pace of import substitution and achieve new growth .
-
CDE publicly solicits opinions on "Technical Guidelines for Clinical Evaluation of Intravenous Anesthetics"
Time of Update: 2021-12-29
On December 7, CDE issued the "Technical Guidelines for the Clinical Evaluation of Intravenous Anesthetics" for soliciting comments.
The time limit for soliciting opinions is 1 month from the date of publication .
"Technical Guidelines for Clinical Evaluation of Intravenous Anesthetics (Draft for Comment)" Feedback Form 3.
-
Under the implementation of the new version of the Pharmacopoeia, microbiological testing equipment in the subdivision of pharmaceutical equipment is promising
Time of Update: 2021-12-29
The 2021 semi-annual report of Tailin Biology shows that the company's main business is the research and development, manufacturing and sales of pharmaceutical equipment such as microbial detection and control technology system products and organic matter analysis instruments .
-
Since December, many Chinese and foreign pharmaceutical companies have announced that they will "hand in hand" to develop new drugs!
Time of Update: 2021-12-28
According to the agreement, Deqi Pharmaceuticals will be responsible for the development of the clinical trial and provide financial support, and will have the global commercialization and development rights of ATG-017; and Bristol-Myers Squibb will provide dose ramping and dose expansion of the combination therapy Odivo® needed in research .
-
What are the reasons behind the recent surge in prices of Chinese medicine products?
Time of Update: 2021-12-28
On December 13, China Resources Sanjiu replied to investors on the interactive platform that due to the continuous increase in overall costs in recent years and other reasons, the ex-factory price of the company's Angong Niuhuang Wan has increased this year .
-
The number of pharmaceutical companies listed on the Sci-tech Innovation Board hit a new high, reaching 34 in 2021
Time of Update: 2021-12-28
In these three years, the number of pharmaceutical and biological companies listed on the Sci-tech Innovation Board has continued to hit new highs, from 14 listed in 2019 to 28 in 2020.
-
20 gynecological Chinese patent medicine into pharmacies sweet and pastry!
Time of Update: 2021-12-28
2021E: TOP20 gynecological Chinese patent medicine brands in physical pharmacies in key citiesSource: Mi Nei. com's terminal competition pattern of physical pharmacies in key citiesAmong the TOP20 brands, Dingkundan of Shanxi Guangyuyuan National Medicines, Jieryin Lotion of Sichuan Enwei Pharmaceutical, and Baofukang Suppository of Hainan Bikai Pharmaceutical are ranked in the top three; in terms of the number of brands, Zhuzhou Qianjin Pharmaceutical There are 4 at most, and Jiawei Xiaoyao pills have been added compared to last year .
-
With the continuous emergence of innovative achievements, the license outs of domestic pharmaceutical companies are becoming more frequent
Time of Update: 2021-12-28
It is understood that in the near future, Shanghai Pharmaceuticals has also announced an exclusive license agreement with HUYABIO, authorizing it to obtain the rights to manufacture, develop and commercialize SPH6162 outside of China .
-
The procurement of "three high" drugs in 14 provinces will start with 38 varieties...
Time of Update: 2021-12-28
On December 13, the Office of the Procurement Leading Group of the Alliance of Fourteen Provinces (autonomous Regions, Municipalities, and Corps) led by the Henan Provincial Medical Insurance Bureau issued the "Henan, Jin, Mongolia, Jiangxi, Guangdong, Guiyu, Gui Yu, Yunnan, Shaanxi and Qing Ningxin Corps Fourteen Provinces (districts, cities, corps) Corps) Pharmaceutical Joint Purchase Documents (Draft for Solicitation of Comments)", soliciting opinions from the public until December 15 .
-
700 million cardiovascular injections!
Time of Update: 2021-12-28
According to data from Meinenet, in 2020, the sales of nicorandil for terminal injection in China's public medical institutions exceeded the 700 million yuan mark, an increase of more than 50% year-on-year in the first half of this year, and the only manufacturer was Beijing Sihuan Kebao Pharmaceutical .
-
Simcere Pharmaceuticals declares new drug for Alzheimer's disease
Time of Update: 2021-12-28
This protein is not only related to the β-amyloid peptide polymerized into plaques that is widely observed in AD patients, but also to Alzheimer's disease (AD ) Other pathological factors have adverse effects, including tau pathological manifestations, neuroinflammation and impaired synaptic function .
-
What can pharmaceutical companies do to help Chinese medicine "go global"?
Time of Update: 2021-12-28
In this context, pharmaceutical companies can continue to promote the development of the Chinese medicine industry in a high-quality direction through technological innovation, the development of modern Chinese medicine scientific research and industrial production technology .
-
CD22 ADC: Pfizer's "Inizumab ozogamicin" will be approved soon
Time of Update: 2021-12-28
The approval is based on the results of the Phase 3 INO-VATEALL trial, a randomized, open-label, international, multi-center study that included 326 adult patients with relapsed or refractory B-cell ALL and compared the efficacy of BESPONSA with standard chemotherapy And security .
-
The opportunity to "get on the bus" in the pharmaceutical sector has arrived!
Time of Update: 2021-12-28
Since November, the pharmaceutical sector has rebounded, with Pharmaceutical Biology (Shenwan) rising by more than 3%, and public offerings have also actively deployed the pharmaceutical track . Acc
-
Regal and Eli Lilly join hands in the industry: License-out projects for Chinese pharmaceutical companies will become increasingly popular
Time of Update: 2021-12-28
According to the terms of the agreement, Jiyu Medicine will exclusively license the development, production and commercialization rights of the KRAS inhibitor JMKX1899 with independent intellectual property rights outside the Greater China Region to Huya, and the relevant rights and interests of JMKX1899 in the Greater China Region will remain with Jimin Trust.
-
Pharmacy services in pharmacies begin to grade
Time of Update: 2021-12-28
2. Health protection function: patient-centered, drug treatment management is the core content, and professional pharmacy services are provided .
In addition, the document divides the professional services provided by social pharmacies into three levels: primary pharmacy, basic pharmacy, and advanced pharmacy .
-
The effect is amazing!
Time of Update: 2021-12-28
Among the 252 patients with CLL/SLL who had previously received BTKi treatment and whose curative effect was assessable, 171 had a response, including 2 CR, 137 PR, 32 partial remission with persistent lymphocytosis (PR-1), 62 SD, ORR 68% .
